FI952746A0 - Polymeeriin sitoutuneen kamptotesiinijohdannaiset - Google Patents

Polymeeriin sitoutuneen kamptotesiinijohdannaiset

Info

Publication number
FI952746A0
FI952746A0 FI952746A FI952746A FI952746A0 FI 952746 A0 FI952746 A0 FI 952746A0 FI 952746 A FI952746 A FI 952746A FI 952746 A FI952746 A FI 952746A FI 952746 A0 FI952746 A0 FI 952746A0
Authority
FI
Finland
Prior art keywords
pct
formula
camptothecin
units represented
hydroxy
Prior art date
Application number
FI952746A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI952746A (fi
Inventor
Francesco Angelucci
Antonino Suarato
Original Assignee
Pharmacia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Spa filed Critical Pharmacia Spa
Publication of FI952746A0 publication Critical patent/FI952746A0/fi
Publication of FI952746A publication Critical patent/FI952746A/fi

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
FI952746A 1993-10-08 1995-06-05 Polymeeriin sitoutuneen kamptotesiinijohdannaiset FI952746A (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939320781A GB9320781D0 (en) 1993-10-08 1993-10-08 Polymer-bound camptothecin derivatives
PCT/EP1994/003154 WO1995010304A1 (en) 1993-10-08 1994-09-21 Polymer-bound camptothecin derivatives

Publications (2)

Publication Number Publication Date
FI952746A0 true FI952746A0 (fi) 1995-06-05
FI952746A FI952746A (fi) 1995-06-05

Family

ID=10743226

Family Applications (1)

Application Number Title Priority Date Filing Date
FI952746A FI952746A (fi) 1993-10-08 1995-06-05 Polymeeriin sitoutuneen kamptotesiinijohdannaiset

Country Status (24)

Country Link
US (1) US5773522A (hu)
EP (1) EP0673258B1 (hu)
JP (1) JPH08504217A (hu)
KR (1) KR100359005B1 (hu)
CN (1) CN1138565C (hu)
AT (1) ATE239507T1 (hu)
AU (1) AU679788B2 (hu)
CA (1) CA2150132A1 (hu)
DE (1) DE69432627T2 (hu)
DK (1) DK0673258T3 (hu)
ES (1) ES2198421T3 (hu)
FI (1) FI952746A (hu)
GB (1) GB9320781D0 (hu)
HU (1) HU215588B (hu)
IL (1) IL111173A (hu)
MY (1) MY116624A (hu)
NZ (1) NZ273952A (hu)
PL (1) PL178132B1 (hu)
PT (1) PT673258E (hu)
RU (1) RU2149646C1 (hu)
TW (1) TW316905B (hu)
UA (1) UA42706C2 (hu)
WO (1) WO1995010304A1 (hu)
ZA (1) ZA947823B (hu)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5880131A (en) * 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
US5965566A (en) * 1993-10-20 1999-10-12 Enzon, Inc. High molecular weight polymer-based prodrugs
US5646159A (en) * 1994-07-20 1997-07-08 Research Triangle Institute Water-soluble esters of camptothecin compounds
DE19512484A1 (de) 1995-04-04 1996-10-17 Bayer Ag Kohlenhydratmodifizierte Cytostatika
SG50747A1 (en) * 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
CA2192725C (en) * 1995-12-28 2004-04-20 Kenji Tsujihara Camptothecin derivatives
US6441025B2 (en) * 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
DK0934329T3 (da) * 1996-09-30 2002-04-08 Bayer Ag Glycokonjugater af modificerede camptothecinderivater (20-O-binding)
DE19640969A1 (de) * 1996-10-04 1998-04-16 Bayer Ag 20-0-verknüpfte Glycokonjugate von Camptothecin
ID23424A (id) 1997-05-14 2000-04-20 Bayer Ag Glikokonjugat dari 20(s)-kamptotesin
GB9721069D0 (en) * 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
GB9721070D0 (en) * 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Bioactive derivatives of camptothecin
US6153655A (en) 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
GB9915180D0 (en) * 1999-06-29 1999-09-01 Pharmacia & Upjohn Spa Antitumour compound
WO2001024763A2 (en) 1999-10-01 2001-04-12 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US20030054977A1 (en) * 1999-10-12 2003-03-20 Cell Therapeutics, Inc. Manufacture of polyglutamate-therapeutic agent conjugates
WO2001036002A1 (en) * 1999-11-17 2001-05-25 School Of Pharmacy, University Of London Conjugates of hpma copolymer and ellipticin
US20020077290A1 (en) * 2000-03-17 2002-06-20 Rama Bhatt Polyglutamic acid-camptothecin conjugates and methods of preparation
GB0008928D0 (en) * 2000-04-11 2000-05-31 Pharmacia & Upjohn Spa A method of administering an antitumour compound
US6350756B1 (en) 2001-01-18 2002-02-26 California Pacific Medical Center Camptothecin derivatives
US6403604B1 (en) 2001-03-01 2002-06-11 California Pacific Medical Center Nitrogen-based camptothecin derivatives
US6855720B2 (en) 2001-03-01 2005-02-15 California Pacific Medical Center Nitrogen-based camptothecin derivatives
WO2003033525A1 (en) * 2001-10-12 2003-04-24 Debio Recherche Pharmacuetique S.A. Amino-substituted camptothecin polymer derivatives and use of the same for the manufacture of a medicament
AU2003243380A1 (en) 2002-06-03 2003-12-19 California Pacific Medical Center Nitrogen-based homo-camptothecin derivatives
US7875602B2 (en) 2005-10-21 2011-01-25 Sutter West Bay Hospitals Camptothecin derivatives as chemoradiosensitizing agents
CN101265331B (zh) * 2007-03-12 2010-10-13 中国科学院化学研究所 Peg改性phpma材料及其制备方法
US9895449B2 (en) 2010-05-25 2018-02-20 Syndevrx, Inc. Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof
ES2853204T3 (es) 2010-05-25 2021-09-15 Syndevrx Inc Inhibidores de MetAP2 conjugado con polímero, y métodos terapéuticos de uso de los mismos
EA033912B1 (ru) 2013-04-10 2019-12-09 Синдевркс, Инк. ИНГИБИТОРЫ MetAP2 И СПОСОБЫ ЛЕЧЕНИЯ ОЖИРЕНИЯ
EP3040393B1 (en) 2013-08-26 2020-09-30 Japan Science and Technology Agency Adhesive
CA3005450A1 (en) 2015-12-10 2017-06-15 Syndevrx, Inc. Fumagillol derivatives and polymorphs thereof
CA3239447A1 (en) 2016-01-11 2017-07-20 Syndevrx, Inc. Treatment for tumors driven by metabolic dysfunction
EP3870231A1 (en) 2018-10-26 2021-09-01 Syndevrx, Inc. Biomarkers of metap2 inhibitors and applications thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4943579A (en) * 1987-10-06 1990-07-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Water soluble prodrugs of camptothecin
GB9200247D0 (en) * 1992-01-07 1992-02-26 Erba Carlo Spa Pharmaceutical compositions containing polymer derivative-bound anthracycline glycosides and a method for their preparation
US5258453A (en) * 1992-01-21 1993-11-02 University Of Utah Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light
GB9213077D0 (en) * 1992-06-19 1992-08-05 Erba Carlo Spa Polymerbound taxol derivatives
GB9309663D0 (en) * 1993-05-11 1993-06-23 Erba Carlo Spa Biologically active compounds

Also Published As

Publication number Publication date
EP0673258B1 (en) 2003-05-07
MY116624A (en) 2004-03-31
ZA947823B (en) 1995-07-03
PL178132B1 (pl) 2000-03-31
IL111173A (en) 1998-10-30
GB9320781D0 (en) 1993-12-01
AU679788B2 (en) 1997-07-10
WO1995010304A1 (en) 1995-04-20
JPH08504217A (ja) 1996-05-07
HU215588B (hu) 1999-01-28
IL111173A0 (en) 1994-12-29
KR100359005B1 (ko) 2003-04-26
CN1115564A (zh) 1996-01-24
NZ273952A (en) 1996-10-28
HUT71678A (en) 1996-01-29
CN1138565C (zh) 2004-02-18
RU2149646C1 (ru) 2000-05-27
PL309328A1 (en) 1995-10-02
ES2198421T3 (es) 2004-02-01
HU9502084D0 (en) 1995-09-28
UA42706C2 (uk) 2001-11-15
US5773522A (en) 1998-06-30
RU95112841A (ru) 1997-06-27
FI952746A (fi) 1995-06-05
ATE239507T1 (de) 2003-05-15
TW316905B (hu) 1997-10-01
EP0673258A1 (en) 1995-09-27
DK0673258T3 (da) 2003-08-25
AU7783694A (en) 1995-05-04
DE69432627D1 (en) 2003-06-12
CA2150132A1 (en) 1995-04-20
PT673258E (pt) 2003-09-30
DE69432627T2 (de) 2004-03-25

Similar Documents

Publication Publication Date Title
DK0673258T3 (da) Polymerbundne camptothecinderivater
BR9408246A (pt) Composto derivado de 3-azabicicloalcano N-substituído
MX9408969A (es) Composisciones farmaceuticas que comprenden microparticulas biodegradables y biocompatibles para el tratamiento de transtornos psicoticos, su uso y procedimiento para prepararlas.
BG100951A (en) Novel erythromycin derivatives, method for their preparation and their use as drugs
CA2419801A1 (en) Steroid derived antibiotics
DE69021176D1 (de) Polypeptid und Verfahren zu dessen Herstellung.
BG103673A (en) 3'-n-oxide, 3'-n-dimethylamine, 9-oxime derivatives of erythromycin a
DK0819132T3 (da) Fremgangsmåde til fremstilling af anthracyclin-antibiotika
EP0450420A3 (en) Dihydropyridines substituted by heterocycles, process for their preparation and their use in medicaments
IL125926A0 (en) Compounds related to the amidinium family pharmaceutical compositions containing them and uses thereof
AU6257394A (en) New derivatives of glutamic and aspartic acids, a method of preparing them, and their use as drugs for enhancing memory and learning
TW268015B (hu)
PH24709A (en) Allylmercaptoacetylsydnonimines and pharmaceutical compositions thereof
IL108856A0 (en) Hydroxymethyl-furazancarboxylic acid derivatives, their preparation and pharmaceutical compositions containing them
MY109729A (en) Benzofuranylimidazole derivatives, a process for the preparation and therapeutical compositions containing the same
HUP9802072A2 (hu) Benzo-tiopiráno-indazol-származékok és az ezeket tartalmazó gyógyszerkészítmények
DK0874863T3 (da) 3-deoxy-3-descladinose-derivater fra erythromycin A og B
ES476077A1 (es) Un procedimiento para preparar derivados del acido 1,3-tia- zol-glioxilico.